|
|
Overview of the 2023 GOLD Guidelines for COPD
Target Audience
The educational design of this activity addresses the needs of primary care providers (PCPs), including physicians, nurse practitioners, and physician assistants who manage patients with chronic obstructive pulmonary disease (COPD).
Program Overview
During the first activity of the series, expert faculty will present and discuss key updates to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Report for Prevention, Diagnosis, and Management of COPD. Th... |
|
|
Surgical Solutions to Achieve and Maintain Visual Gains in nAMD
Management of patients with retinal vascular diseases utilizing intravitreal anti-vascular endothelial growth factor (VEGF) therapy has provided significant enhancements to visual acuity outcomes, but maintenance of these visual acuity gains requires frequent treatment and monitoring. The frequency of these clinical visits can be a challenge to sustain and places a considerable burden on the patient and caregivers―often resulting in undertreatment of disease due to loss of adherence. To addr... |
|
|
Surgical Solutions to Achieve and Maintain Visual Gains in nAMD
Management of patients with retinal vascular diseases utilizing intravitreal anti-vascular endothelial growth factor (VEGF) therapy has provided significant enhancements to visual acuity outcomes, but maintenance of these visual acuity gains requires frequent treatment and monitoring. The frequency of these clinical visits can be a challenge to sustain and places a considerable burden on the patient and caregivers―often resulting in undertreatment of disease due to loss of adherence. To addr... |
|
|
Best of IBD Summit: Navigating Loss of Response, Maintenance Therapy, and Fistulizing CD
Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the main subtypes, is a chronic relapsing condition characterized by an overly active immune response in the gut, resulting in bowel inflammation and ulceration. Given the increasing prevalence of disease and influx of available biologics and small molecule therapies, gastroenterology fellows can benefit from ongoing education regarding the diagnosis, classification, and evidence-based management of patient... |
|
|
Best of IBD Summit: Navigating Loss of Response, Maintenance Therapy, and Fistulizing CD
Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the main subtypes, is a chronic relapsing condition characterized by an overly active immune response in the gut, resulting in bowel inflammation and ulceration. Given the increasing prevalence of disease and influx of available biologics and small molecule therapies, gastroenterology fellows can benefit from ongoing education regarding the diagnosis, classification, and evidence-based management of patient... |
|
|
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ... |
|
|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |
|
|
PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team
Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati... |
|